Clinical Trials Browser

Phase 2 × ibrutinib × Classical hematology × Clear all

NCT05694312 2023-12-01

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Phase 2 Recruiting

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell